$Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy$

Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy

Bibliographic Details
Main Authors:	Po-Ta Lai, Han-Chi Tseng
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Dermatologica Sinica
Online Access:	http://www.dermsinica.org/article.asp?issn=1027-8117;year=2022;volume=40;issue=4;spage=237;epage=238;aulast=Lai

Similar Items

Bullous pemphigoid developed after dramatic improvement of severe prurigo nodularis
by: Tomoko Hiraiwa, et al.
Published: (2023-08-01)

Recalcitrant prurigo nodularis after COVID‐19 vaccination and successfully treated by dupilumab
by: Shang‐shang Wang, et al.
Published: (2023-09-01)

Successful treatment of refractory prurigo nodularis with abrocitinib
by: Fang Sun, et al.
Published: (2024-03-01)

Methotrexate for refractory prurigo nodularis
by: Mariam Al Zaabi, et al.
Published: (2017-01-01)

Dupilumab as promising treatment for prurigo nodularis: current evidences
by: Ludovica Toffoli, et al.
Published: (2022-04-01)

Dupilumab for the treatment of prurigo nodularis: A systematic review
by: Peng Cao, et al.
Published: (2023-01-01)

Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab
by: Joshua D. Bloomstein, BS, et al.
Published: (2021-12-01)

Treatment of refractory prurigo nodularis with a monoclonal antibody dupilumab with surprising clinical response
by: Juliana P Alves, et al.
Published: (2023-01-01)

Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy
by: Liu T, et al.
Published: (2021-03-01)

Effective treatment of prurigo nodularis with dupilumab: A case report
by: Chuan Liu, et al.
Published: (2022-01-01)

Early-onset, severe prurigo nodularis in a young child with atopic dermatitis treated successfully with dupilumab
by: Henrietta Albela, et al.
Published: (2022-01-01)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
by: Qijun Wang, et al.
Published: (2023-09-01)

Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study
by: Katina J. Selvaraj, BSc, BA, MD, et al.
Published: (2023-06-01)

Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks
by: Claudia Paganini, et al.
Published: (2024-02-01)

Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy
by: S. Ferrucci, et al.
Published: (2021-05-01)

Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series
by: Louise Lönndahl, et al.
Published: (2022-08-01)

Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report
by: Ilaria Sammarra, et al.
Published: (2022-05-01)

A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis
by: Zhixin Zhang, et al.
Published: (2023-08-01)

Skin Microbiome in Prurigo Nodularis
by: Klaudia Tutka, et al.
Published: (2023-04-01)

Immunotargets and Therapy for Prurigo Nodularis
by: Labib A, et al.
Published: (2022-04-01)

Prurigo Nodularis With Cutaneous Horn
by: Thadeus Joseph, et al.
Published: (1997-01-01)

Dermatoscopic features of prurigo nodularis
by: Pragya A Nair, et al.
Published: (2019-01-01)

Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response
by: Husein Husein-ElAhmed, et al.
Published: (2022-04-01)

Case report: Successful treatment of non-bullous lichen planus pemphigoides with dupilumab
by: Si-Zhe Li, et al.
Published: (2022-12-01)

Response: Management challenges in prurigo nodularis
by: Jennifer M. Fernandez, et al.
Published: (2022-01-01)

Molecular mechanisms of pruritus in prurigo nodularis
by: Yixin Shao, et al.
Published: (2023-11-01)

Prurigo nodularis responding to intravenous immunoglobulins
by: Koray Durmaz, et al.
Published: (2022-07-01)

Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report
by: Liu JH, et al.
Published: (2023-06-01)

Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
by: Roberto Russo, et al.
Published: (2022-06-01)

Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient
by: Albert E. Zhou, MD, PhD, et al.
Published: (2022-11-01)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
by: Yihua Zhang, et al.
Published: (2021-10-01)

Bullous Pemphigoid Successfully Treated with Rituximab
by: Nuno Silva, et al.
Published: (2017-03-01)

Lichen planus pemphigoides successfully treated with dupilumab
by: Peter Yi Ch’en, BS, et al.
Published: (2023-01-01)

Inpatient Burden of Prurigo Nodularis in the United States
by: Katherine A. Whang, et al.
Published: (2019-08-01)

Tofacitinib for Prurigo Nodularis: A Case Report
by: Peng C, et al.
Published: (2022-03-01)

Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis
by: Christina D. Kwon, et al.
Published: (2019-09-01)

Prurigo nodularis in vitiligo patches: An unusual observation
by: Karim Saleh, MD, PhD
Published: (2020-09-01)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
by: S. Morteza Seyed Jafari, et al.
Published: (2021-01-01)

Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types
by: Tianmeng Yan, et al.
Published: (2023-07-01)

Distinguishing truly recalcitrant prurigo nodularis from poor treatment adherence: a response to treatment-resistant prurigo nodularis [Response to letter]
by: Kowalski EH, et al.
Published: (2019-05-01)